Rege Nephro Co., Ltd.

About Rege Nephro Co., Ltd.

Regenephro Co., Ltd. is a global leader leveraging iPS cell technology to innovate treatment options for intractable diseases of the kidney, liver, and pancreas, aiming to create a future where people worldwide are free from suffering due to illness.

Products & Services

iPS Cell Technology-Based Treatments:Developing innovative treatment options for intractable diseases of the kidney, liver, and pancreas using iPS cell technology.

Tamibarotene:Designated as an orphan drug for autosomal dominant polycystic kidney disease.

RN-014 (ADPKD treatment drug)

Tamibarotene (for ADPKD)

Specialties

iPS Cell Technology Treatment of Intractable Diseases (Kidney, Liver, Pancreas) Orphan Drug Development iPS cell-derived nephron technology Regenerative therapies for kidney, liver, pancreas ADPKD drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Note T: - FT: Convertible Note	A: 10600000 MR: - FA: $10.6M FAN: 10600000	D: 2026-07-21 FD: 2026-07-21	13 investors
2	RT: Series B T: - FT: Series B	A: 172000000 MR: - FA: 22.5 billion yen FAN: 172000000	D: 2024-10-07 FD: 2024-10-07	20 investors

Convertible Note Latest

2026-07-21

$10.6M

13 investors (Pro only)

Series B 2024-10-07

$172.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kenji Osafune

Director and Chief Scientific Advisor (Founder)

K

Kenji Osafune

Founder (Director/Chief Scientific Advisor), Professor at Kyoto University iPS Cell Research Institute

A

Akifumi Morinaka

Representative Director CEO

森

森中紹文

代表取締役CEO

長

長船健二

最高科学顧問（創設者）京都大学iPS細胞研究所教授

山

山口勝久

取締役/CFO 管理本部長

View 25 more team members with Pro

Unlock Full Team Directory

Recent News